Trial Profile
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Dec 2020
Price :
$35
*
At a glance
- Drugs Eluxadoline (Primary)
- Indications Irritable bowel syndrome
- Focus Registrational; Therapeutic Use
- Acronyms IBS-3001
- Sponsors Furiex Pharmaceuticals
- 13 Oct 2020 Results of aggregated pooled analysis from two phase III studies: NCT01553591 and NCT01553747 and one phase IV study: RELIEF presented at the 28th United European Gastroenterology Week
- 19 May 2020 Results of an analysis assessing range of abdominal and bowel symptoms in patients with irritable bowel syndrome with diarrhea reporting inadequate symptom control with Loperamide from two Phase 3 trials (NCT01553591 and NCT01553747) and one phase IV trial (RELIEF: NCT02959983), were published in Gasteroenterology in conjunction with Digestive Disease Week 2020.
- 01 Nov 2017 Results of pooled post hoc analysis of IBS-3001 and IBS-3002 trials assessing responder and non-responder rates over 4-week intervals and the proportion of responders/non-responders who continued or discontinued treatment presented at the 25th United European Gastroenterology Week